succinato sódico de metilpredinisolona
fresenius kabi brasil ltda - succinato sÓdico de metilprednisolona - glicocorticoides sistemicos
brometo de pancurônio
fresenius kabi brasil ltda - brometo de pancurÔnio - bloqueador neuromuscular
jayempi
nova laboratories ireland limited - azathioprine - rejeição de enxerto - imunossupressores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
reverso
cristÁlia produtos quÍmicos farmacÊuticos ltda. - sugamadex sÓdico - outros prods nao enquadrados em classe terapeutica especif
sug
biolab sanus farmacÊutica ltda - sugamadex sÓdico - outros prods nao enquadrados em classe terapeutica especif
imuran 25 mg comprimido revestido por película
aspen pharma trading ltd. - azatioprina - comprimido revestido por película - 25 mg - azatioprina 25 mg - azathioprine - n/a - duração do tratamento: longa duração
dexmedetomidina kalceks 100 µg/ml concentrado para solução para perfusão
kalceks, as - dexmedetomidina - concentrado para solução para perfusão - 100 µg/ml - dexmedetomidina, cloridrato 0.118 mg/ml - dexmedetomidine - genérico - duração do tratamento: curta ou média duração
dexmedetomidina kabi 100 µg/ml concentrado para solução para perfusão
fresenius kabi pharma portugal, lda. - dexmedetomidina - concentrado para solução para perfusão - 100 µg/ml - dexmedetomidina, cloridrato 0.118 mg/ml - dexmedetomidine - genérico - duração do tratamento: curta ou média duração
azafalk 100 mg comprimido revestido por película
dr. falk pharma gmbh - azatioprina - comprimido revestido por película - 100 mg - azatioprina 100 mg - azathioprine - n/a - duração do tratamento: longa duração
dexmedetomidina b. braun 100 µg/ml concentrado para solução para perfusão
b. braun melsungen a.g. - dexmedetomidina - concentrado para solução para perfusão - 100 µg/ml - dexmedetomidina, cloridrato 118 µg/ml - dexmedetomidine - genérico - duração do tratamento: curta ou média duração